Showing results (61-70 of 79) with videos related to

Sort By:
Pageof 8
JNCI Cancer Spectrum|April 16, 2024
Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrationsAndrea Necchi, Rodryg Ramlau, Alejandro Falcón González, et al.
Cancer Immunology, Immunotherapy : CII|May 24, 2026
Real-world efficacy and safety of immune checkpoint blockades in advanced urothelial carcinoma with histologic variant subtypes: the pembroblad studyKarim Amrane, Luca Campedel, Fabien Moinard-Butot, et al.
European Journal of Cancer (Oxford, England : 1990)|April 11, 2020
Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE studyAlexis B Cortot, Clarisse Audigier-Valette, Olivier Molinier, et al.
European Journal of Cancer (Oxford, England : 1990)|January 18, 2022
Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinomaGuru P Sonpavde, Cora N Sternberg, Yohann Loriot, et al.
Nature Medicine|April 8, 2025
Broad versus limited gene panels to guide treatment in patients with advanced solid tumors: a randomized controlled trialOlivier Trédan, Damien Pouessel, Nicolas Penel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2024
Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial CancerYohann Loriot, Arjun V Balar, Daniel P Petrylak, et al.
World Journal of Urology|July 1, 2021
Risk factors associated with positive surgical margins' location at radical cystectomy and their impact on bladder cancer survivalFrancesco Claps, Maaike W van de Kamp, Roman Mayr, et al.
Clinical Genitourinary Cancer|December 29, 2019
Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor GroupMarine Sroussi, Reza Elaidi, Aude Fléchon, et al.
European Urology|November 12, 2025
Nivolumab in Metastatic Clear-cell Renal Cell Carcinoma: An Integrative Biomarker Analysis from the NIVOREN GETUG-AFU 26 Phase 2 StudyRonan Flippot, Yann-Alexandre Vano, Cécile Dalban, et al.
The Lancet. Oncology|November 28, 2021
Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trialPatrick Y Wen, Alexander Stein, Martin van den Bent, et al.
Pageof 8